A joint collective between the AUA, the American Society for Radiation Oncology (ASTRO), and the Society of Urologic Oncology (SUO) has released a new evidence-based clinical guideline for the management of clinically localized prostate cancer.
The guideline divides localized prostate cancer into low-, intermediate-, and high-risk disease.
“It’s been quite some time since the AUA or ASTRO had refreshed the prostate cancer guidelines and there’s been quite a bit of new evidence that’s come along over the last several years. It was important to incorporate the evolution of care standards into the guidelines,” Martin Sanda, MD, of Emory University School of Medicine, Atlanta, who served as the chair of the guideline development panel, told Urology Times. “The guidelines were quite limited in terms of their scope and directionality previously, as well.”
Over the past 5-6 years, multiple randomized clinical trials have come forward that were not included in the prior version of the guideline. This new guideline has the opportunity to provide a more robust and comprehensive framework so that urologists, radiation oncologists, and oncologists can help ensure a consistent level of care quality for a man with newly diagnosed, localized prostate cancer.
The guideline includes updates on shared decision-making, care options based on cancer severity, and specific care options such as active surveillance, radical prostatectomy, high-intensity focused ultrasound, and focal therapy. Once the collaborators agreed on the guideline, it was passed on to peer reviewers of varying backgrounds before being approved by the AUA, ASTRO, and SUO Board of Directors.